课题基金 / 基金详情

Teratogenicity assessment of new antiviral drugs using 3D morphogenesis models

Teratogenicity assessment of new antiviral drugs using 3D morphogenesis models
使用 3D 形态发生模型评估新型抗病毒药物的致畸性
批准号:
10741474
负责人:
YUSUKE MARIKAWA
金额:
$15.65万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-08-10 至 2025-07-31

项目摘要

项目成果

YUSUKE MARIKAWA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Proposal Abstract Various drugs are known to be teratogenic, causing miscarriages or birth defects, when used during pregnancy. However, teratogenicity is unclear for many other drugs, particularly those that were recently marketed. Because of the ongoing COVID-19 pandemic/endemic, many investigators are developing new antiviral drugs against SARS-CoV-2. Currently, three antivirals are approved or granted the emergency use authorization by the FDA, namely remdesivir, molnupiravir, and Paxlovid. Yet studies on their teratogenicity are scarce. As COVID-19 still persists with the emergence of immune escape variants, many people, including those of childbearing potential, may require antiviral treatment. For physicians to provide proper advice for their patients, the teratogenicity of the antivirals should be studied sufficiently. Previously, we invented the mouse and human stem cell-based 3D morphogenesis models, which recapitulate the key features of early embryogenesis in vitro and can serve as effective tools to sensitively and specifically detect various teratogenic chemicals. Our Preliminary Studies using these morphogenesis models suggest that the anti-COVID-19 drugs, particularly remdesivir and molnupiravir, impair embryogenesis at the concentrations close to their therapeutic plasma levels in human. These observations necessitate further investigations into the teratogenic potential of the antivirals, as proposed in this application. Specifically, we will (1) characterize the molecular impact of the new antivirals on the morphogenesis models, (2) explore the possible teratogenic mechanisms of the new antivirals, and (3) examine the teratogenic effects of the new antivirals with the mouse whole embryo culture. The proposed experiments should yield valuable information pertinent to their teratogenic potential, such as the concentration-effect relationship and molecular mechanisms of actions, and help in the design and interpretation of animal- and human-based studies in an effective manner.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Human pluripotent stem cell-based assessment of dolutegravir teratogenicity
  • 批准号:
    10231131
  • 项目类别:
  • 资助金额:
    $7.8万
  • 财政年份:
    2020
  • 负责人:
    YUSUKE MARIKAWA
  • 依托单位:
Human pluripotent stem cell-based assessment of dolutegravir teratogenicity
  • 批准号:
    10043778
  • 项目类别:
  • 资助金额:
    $7.78万
  • 财政年份:
    2020
  • 负责人:
    YUSUKE MARIKAWA
  • 依托单位:
Regeneration of meiotic spindle during oocyte vitrification
  • 批准号:
    8242474
  • 项目类别:
  • 资助金额:
    $7.5万
  • 财政年份:
    2012
  • 负责人:
    YUSUKE MARIKAWA
  • 依托单位:
Regeneration of meiotic spindle during oocyte vitrification
  • 批准号:
    8518432
  • 项目类别:
  • 资助金额:
    $7.12万
  • 财政年份:
    2012
  • 负责人:
    YUSUKE MARIKAWA
  • 依托单位:
海外基金